Speakers

Khuloud Al-Jamal

Place of Birth : Jordan
Position : Chair of Drug Delivery & Nanomedicine, King’s College London, UK
Field of study : Design and development of novel nanoscale delivery systems; drug, protein, nucleic acids and radionuclide delivery for therapeutic or diagnostic applications; preclinical translation
H. Index : 34

Professor Khuloud T. Al-Jamal is a Chair of Drug Delivery & Nanomedicine, King’s College London. She is also a registered pharmacist at the General Pharmaceutical Council. She started her academic career as a lecturer at King’s College London in 2011. She completed her pre-registration pharmacy training at The University College London Hospital and was awarded the Overseas Research Award Scheme (ORSA) Scholarship from The University of London (2000-2004) to complete her Ph.D. in Drug Delivery from The School of Pharmacy, the University of London (currently known as UCL-School of Pharmacy). She was awarded the prestigious CW Maplethorpe Research and Teaching Postdoctoral Fellowship from The University of London (2005-2007) to explore the use of cationic dendrimers as anti-angiogenic agents for growth inhibition of solid and metastatic tumors. She has developed extensive experience in designing and developing novel nanoscale delivery systems including dendrimers, liposomes, quantum Dots (QDs), polymers, viral vectors, chemically functionalised carbon nanotubes and graphene oxide. Her current work involves pre-clinical translation of novel nanomaterials designed specifically for drug, protein, nucleic acids and radionuclide delivery for therapeutic or diagnostic applications. She is a management board member and is on the steering committee of the London Centre of Nanotechnology and the Children Brain Tumour Drug Delivery Consortium. She is on the Editorial Board of Biomaterials Science (RSC), Scientific Reports (Nature Publisher) and Journal of Drug Targeting.

Prof. Khuloud Al-Jamal is an expert in engineering nanomedicines for targeted delivery to cancerous tissues for combinatory therapy. She pioneered functionalized carbon nanotube (CNT)-based vectors to deliver neuroprotective siRNA to rodent’s brain (stroke) (PNAS 2011; PCT Application No.11066) in vivo and was first to discover the ability of CNTs to cross the Blood-Brain Barriers and target glioma in rodent models (Biomaterials 2015; J Control Release 2015, 2016). She reported with collaborators the first evidence of biodegradation of CNTs in the brain in vivo (Nanomedicine 2012) and the first study on the use of filled and functionalized CNTs in live animal imaging and targeted delivery of radiotherapy (Nature Materials 2010). She has published over 100 papers in ISI-refereed International Journals and her work has received citation around 4000 times (H index = 34). She has filed 4 patent applications in the UK and Europe. She has received a number of awards including the prestigious Royal Pharmaceutical Science Award (2012), in recognition of her work in Nanomedicine (third female to receive this award in a 43-year-history). In 2019, She received the Young Investigator Award in Nanomedicine by the Controlled Release Society. She is committed to public engagement, which is evident by being a third-time winner of the Wellcome Trust Image Award (2014, 2015 & 2016). Her lab is funded by funding from EPSRC, BBSRC, Worldwide Cancer Research, Wellcome Trust, British Council, European Commission FP6 & FP7 & Marie Curie Fellowships, and the Brain Tumour Charity.

• Professor in Drug Delivery and Nanomedicine, Institute of Pharmaceutical Science, Department of Pharmacy & Forensic Science, King’s College London, UK, (2016–Present)

• Visiting Professor, University of Sapienza, Rome, Italy, (2019–Present)

• Visiting Professor, Guizhou University, Guiyang, China, (2016 –Present)

• Lecturer/Senior Lecturer/Reader in Nanomedicine, Institute of Pharmaceutical Science, Department of Pharmacy & Forensic Science, King’s College London, UK, (2011 –2016)